T-cell lymphoma is a group of cancers derived from T-cells, which are cells of the immune system that are critical to immune function. Because there are more than 30 identified subtypes of T-cell lymphoma, it can be difficult to make a definitive diagnosis.

Mayo Clinic Laboratories offers extensive testing for detecting and diagnosing T-cell neoplasms, including morphology, immunohistochemistry (IHC), flow cytometry, fluorescence in situ hybridization (FISH), and molecular assays.

“Most T-cell lymphomas are aggressive, but there is a wide variability in outcomes,” Andrew Feldman, M.D., explains in a “Test in Focus” podcast episode. “Some subtypes have an excellent prognosis. So accurate diagnosis and classification is critical.”

Mayo Clinic Laboratories also provides consultations for clinicians around the world to help give them the diagnostic answers needed to treat T-cell lymphoma patients.

“The diagnosis of whether it is neoplastic, a lymphoproliferative disorder, or an overt lymphoma is really critical to the management of the patient,” says Dr. Feldman.

Understanding the molecular underpinnings of the T-cell lymphoma subtypes is key to uncovering new developments that will lead to treatment optimization and improved quality of life for the patient.

“To see something go from a laboratory approach and research-based molecular profiling to clinical application is one of the main reasons we do what we do here,” says Dr. Feldman.

To learn more, listen to this “Answers From the Lab” podcast episode on Mayo Clinic Laboratories Insights.